Joseph Catanzaro
Stock Analyst at Piper Sandler
(2.02)
# 2,957
Out of 4,915 analysts
99
Total ratings
39.51%
Success rate
-6.62%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.46 | +103.25% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.19 | +128.31% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.57 | +133.46% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $20.33 | +121.35% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $66.24 | +26.81% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $112.29 | -2.04% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $36.22 | +4.91% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $14.32 | +4.75% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $59.97 | -11.62% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.38 | +320.17% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $37.24 | +87.97% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.88 | +6.38% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.65 | +1,055.02% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $6.47 | +193.66% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.65 | +466.04% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.35 | +971.43% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $29.85 | +20.60% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.71 | +496.13% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $11.58 | +29.53% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $11.26 | +210.83% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.74 | +504.92% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.28 | +2,243.75% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.19 | +1,580.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $2.01 | +397.51% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.01 | +199.50% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.52 | +1,544.74% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.71 | -52.83% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $21.33 | -6.24% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.03 | -26.11% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $7.63 | +2,522.95% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.50 | +438.46% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.39 | +4,216.55% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.90 | +520.69% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.46
Upside: +103.25%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.19
Upside: +128.31%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.57
Upside: +133.46%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $20.33
Upside: +121.35%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $66.24
Upside: +26.81%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $112.29
Upside: -2.04%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $36.22
Upside: +4.91%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $14.32
Upside: +4.75%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $59.97
Upside: -11.62%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.38
Upside: +320.17%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $37.24
Upside: +87.97%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.88
Upside: +6.38%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.65
Upside: +1,055.02%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $6.47
Upside: +193.66%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.65
Upside: +466.04%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.35
Upside: +971.43%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $29.85
Upside: +20.60%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.71
Upside: +496.13%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $11.58
Upside: +29.53%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $11.26
Upside: +210.83%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.74
Upside: +504.92%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.28
Upside: +2,243.75%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.19
Upside: +1,580.67%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $2.01
Upside: +397.51%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $6.01
Upside: +199.50%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.52
Upside: +1,544.74%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.71
Upside: -52.83%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $21.33
Upside: -6.24%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.03
Upside: -26.11%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $7.63
Upside: +2,522.95%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $6.50
Upside: +438.46%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.39
Upside: +4,216.55%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.90
Upside: +520.69%